Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI-80090
- Development stage
- Preclinical
- Lead developer
- EyePoint Pharmaceuticals
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Intravitreal
01
Overview
IBI-80090 is a preclinical-stage sustained-release formulation of the platinum-based chemotherapeutic agent carboplatin, developed by Icon Bioscience (now EyePoint Pharmaceuticals) for the treatment of retinoblastoma. The drug utilizes the proprietary Verisome drug delivery platform, which consists of a biodegradable, injectable liquid that forms a solid or semi-solid depot upon administration into the eye (typically via intravitreal injection). This technology is designed to provide controlled, long-term release of carboplatin directly to the tumor site, thereby maximizing therapeutic efficacy while minimizing the systemic toxicity and the need for frequent invasive procedures associated with conventional chemotherapy.
- Other names
- Verisome carboplatin
02
Targets
GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on IBI-80090.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI-80090.